Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Pharming Group is back in focus after analysts updated their fair value estimate from €2.11 to €2.36, giving readers fresh context for how the stock is being assessed today. Recent research frames this new €2.36 figure as a balance of optimism around growth potential and caution on execution and valuation, helping you see how bullish and bearish arguments are shaping the story. Read on to see how these moving parts fit together and how you can keep track of the evolving Pharming Group narrative over time.
Stay updated as the Fair Value for Pharming Group shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Pharming Group.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Canaccord initiated coverage on Pharming Group with a positive stance on growth potential, signaling that at least one research house sees room for the business to expand from its current base.
-
The bullish initiation suggests Canaccord views the current Pharming Group valuation as offering upside if the company delivers on its growth plans and executes effectively on its pipeline and commercial priorities.
🐻 Bearish Takeaways
-
Oppenheimer lowered its price target for Pharming Group, which highlights concerns around how previous expectations line up with current execution and risk levels.
-
The reduced target from Oppenheimer points to more caution on valuation, with the firm signaling that investors should be mindful of how growth ambitions, regulatory milestones, and commercial delivery are reflected in the current share price.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 2 risks for Pharming Group. See which could impact your investment.
How This Changes the Fair Value For Pharming Group
-
Fair value updated from €2.11 to €2.36.
-
Revenue growth assumption adjusted from 3.17% to 6.19%.
-
Net profit margin updated from 8.66% to 7.38%.
-
Future P/E multiple revised from 33.72x to 88.56x.
-
Discount rate moved from 5.39% to 5.75%.
Never Miss an Update: Follow The Narrative
Narratives connect Pharming Group's clinical and commercial story to a set of earnings assumptions and fair value estimates. They refresh as new data, approvals, and guidance come through so you can see how the thesis is evolving.
Head over to the Simply Wall St Community and follow the Narrative on Pharming Group to stay up to date on:
-
How RUCONEST is positioned as a cash generator in severe hereditary angioedema while newer therapies emerge around it.
-
Why Joenja is central to Pharming Group's growth plans, including APDS label expansions, pediatric approvals, and international rollouts.
-
The key execution risks around competition in rare disease markets, clinical and regulatory milestones, pricing and access, and returns on future M&A.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PHARM.AS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
